Evidence map›Paper›PMID 31370279›Full record

ArticleCancers2019

Novel Semi-Replicative Retroviral Vector Mediated Double Suicide Gene Transfer Enhances Antitumor Effects in Patient-Derived Glioblastoma Models.

Mijeong Lee, Yeon-Soo Kim, Kyoungmin Lee, Moonkyung Kang, Hyemi Shin, Jeong-Woo Oh, Harim Koo, Donggeon Kim, Yejin Kim, Doo-Sik Kong and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Mijeong LeeDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Yeon-Soo KimGraduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Korea.
Kyoungmin LeeDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Moonkyung KangGraduate School of New Drug Discovery and Development, Chungnam National University, Daejeon 34134, Korea.
Hyemi ShinDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Jeong-Woo OhDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Harim KooDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Donggeon KimInstitute for Refractory Cancer Research, Samsung Medical Center, Seoul 06351, Korea.
Yejin KimDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea.
Doo-Sik KongDepartment of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06531, Korea. kds026@skku.edu.
Do-Hyun NamDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea. nsnam@skku.edu.
Hye Won LeeDepartment of Health Science & Technology, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul 06351, Korea. nsproper@skku.edu.
Samsung (South Korea) · KRChungnam National University · KRSamsung Medical Center · KR

Funding

the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Korean government (MSIT) NRF-2015M3A9B5053642the Bio & Medical Technology Development Program of the National Research Foundation (NRF), funded by the Korean government (MSIT) NRF-2018M3A9B5059544the Korean government (MSIP) NRF-2016R1A5A2945889the National Research Foundation of Korea (NRF), funded by the Ministry of Education, Republic of Korea NRF-2017R1A2B4011780
6 · The paper itself

Abstract

As glioblastomas are mostly localized infiltrative lesions, gene therapy based on the retroviral replicating vector (RRV) system is considered an attractive strategy. Combinations of multiple suicide genes can circumvent the limitations associated with each gene, achieving direct and synergistic cytotoxic effects, along with bystander cell killing. In this study, we constructed a semi-and pseudotyped-RRV (sp-RRV) system harboring two suicide genes-herpes simplex virus type 1 thymidine kinase (

Indexed as

bystander effectdual suicide gene therapyglioblastomapatient-derived glioblastoma stem-like cellssemi- and pseudotyped-retroviral replicating vector

Identifiers

PMID31370279
PMCPMC6721803
OpenAlexW2965200186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.